Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Padrón E[au]:

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. Mesa RA et al. J Natl Compr Canc Netw. (2017)

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Basiorka AA et al. Blood. (2016)

Autoimmune diseases and myelodysplastic syndromes. Komrokji RS et al. Am J Hematol. (2016)

Search results

Items: 1 to 50 of 142

1.

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet.

Itzykson R, Fenaux P, Bowen D, Cross NCP, Cortes J, De Witte T, Germing U, Onida F, Padron E, Platzbecker U, Santini V, Sanz GF, Solary E, Van de Loosdrecht A, Malcovati L.

Hemasphere. 2018 Nov 29;2(6):e150. doi: 10.1097/HS9.0000000000000150. eCollection 2018 Dec.

PMID:
31723789
2.

Non-canonical Transcriptional Consequences of BET Inhibition in Cancer.

Letson C, Padron E.

Pharmacol Res. 2019 Nov 4:104508. doi: 10.1016/j.phrs.2019.104508. [Epub ahead of print] Review.

PMID:
31698067
3.

Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia.

Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE.

Clin Cancer Res. 2019 Oct 21. pii: clincanres.2169.2019. doi: 10.1158/1078-0432.CCR-19-2169. [Epub ahead of print]

PMID:
31636097
4.

Demand for Self-Managed Medication Abortion Through an Online Telemedicine Service in the United States.

Aiken ARA, Starling JE, van der Wal A, van der Vliet S, Broussard K, Johnson DM, Padron E, Gomperts R, Scott JG.

Am J Public Health. 2019 Oct 17:e1-e8. doi: 10.2105/AJPH.2019.305369. [Epub ahead of print]

PMID:
31622157
5.

Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.

Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM.

Leukemia. 2019 Sep 11. doi: 10.1038/s41375-019-0574-x. [Epub ahead of print] No abstract available.

PMID:
31511613
6.

Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Aug 23. doi: 10.1002/ajh.25625. [Epub ahead of print] No abstract available.

PMID:
31444809
7.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
8.

Effects of Corynebacterium bovis on Engraftment of Patient-derived Chronic-Myelomonocytic Leukemia Cells in NSGS Mice.

Vedder AR, Miedel EL, Ragland NH, Balasis ME, Letson CT, Engelman RW, Padron E.

Comp Med. 2019 Aug 1;69(4):276-282. doi: 10.30802/AALAS-CM-18-000138. Epub 2019 Jul 26.

PMID:
31349880
9.

Relapsed Acute Lymphoblastic Leukemia Presenting as Acute Renal Failure.

Rose A, Slone S, Padron E.

Case Rep Nephrol. 2019 May 13;2019:7913027. doi: 10.1155/2019/7913027. eCollection 2019.

10.

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions.

Valent P, Orazi A, Savona MR, Patnaik MM, Onida F, van de Loosdrecht AA, Haase D, Haferlach T, Elena C, Pleyer L, Kern W, Pemovska T, Vladimer GI, Schanz J, Keller A, Lübbert M, Lion T, Sotlar K, Reiter A, De Witte T, Pfeilstöcker M, Geissler K, Padron E, Deininger M, Orfao A, Horny HP, Greenberg PL, Arber DA, Malcovati L, Bennett JM.

Haematologica. 2019 Oct;104(10):1935-1949. doi: 10.3324/haematol.2019.222059. Epub 2019 May 2.

11.

A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res. 2019 Jun;81:56-61. doi: 10.1016/j.leukres.2019.03.008. Epub 2019 Mar 30.

PMID:
31030089
12.

Leveraging Single-Cell RNA Sequencing Experiments to Model Intratumor Heterogeneity.

Ferrall-Fairbanks MC, Ball M, Padron E, Altrock PM.

JCO Clin Cancer Inform. 2019 Apr;3:1-10. doi: 10.1200/CCI.18.00074.

13.

TP53 and therapy-related myeloid neoplasms.

Chung J, Sallman DA, Padron E.

Best Pract Res Clin Haematol. 2019 Mar;32(1):98-103. doi: 10.1016/j.beha.2019.02.009. Epub 2019 Feb 19. Review.

PMID:
30927980
14.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia.

Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E.

Leukemia. 2019 Oct;33(10):2466-2480. doi: 10.1038/s41375-019-0447-3. Epub 2019 Mar 20.

PMID:
30894665
15.

Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.

Komrokji RS, Al Ali NH, Padron E, Cogle C, Tinsley S, Sallman D, Lancet JE, Lis AF.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):251-254. doi: 10.1016/j.clml.2018.12.014. Epub 2019 Jan 2.

PMID:
30852241
16.

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20.

PMID:
30713125
17.

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia.

Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U.

Sci Rep. 2019 Jan 24;9(1):606. doi: 10.1038/s41598-018-37174-6.

18.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

19.

Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Wadleigh M, Walsh K, Bergman MA, Sundar H.

J Natl Compr Canc Netw. 2018 Dec;16(12):1500-1537. doi: 10.6004/jnccn.2018.0088.

PMID:
30545997
20.

Managing Clonal Hematopoiesis in Patients With Solid Tumors.

Bolton KL, Gillis NK, Coombs CC, Takahashi K, Zehir A, Bejar R, Garcia-Manero G, Futreal A, Jensen BC, Diaz LA Jr, Gupta D, Mantha S, Klimek V, Papaemmanuil E, Levine R, Padron E.

J Clin Oncol. 2019 Jan 1;37(1):7-11. doi: 10.1200/JCO.18.00331. Epub 2018 Nov 7. No abstract available.

PMID:
30403571
21.

Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.

PMID:
30390311
22.

Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.

Hunter AM, Zhang L, Padron E.

Curr Treat Options Oncol. 2018 Oct 27;19(12):67. doi: 10.1007/s11864-018-0581-6. Review.

PMID:
30367269
23.

OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms.

Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW.

Cytometry A. 2018 Oct;93(10):982-986. doi: 10.1002/cyto.a.23598. No abstract available.

24.

The impact of Northern Ireland's abortion laws on women's abortion decision-making and experiences.

Aiken ARA, Padron E, Broussard K, Johnson D.

BMJ Sex Reprod Health. 2018 Oct 19. pii: bmjsrh-2018-200198. doi: 10.1136/bmjsrh-2018-200198. [Epub ahead of print]

PMID:
30341065
25.

Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.

Kong G, You X, Wen Z, Chang YI, Qian S, Ranheim EA, Letson C, Zhang X, Zhou Y, Liu Y, Rajagopalan A, Zhang J, Stieglitz E, Loh M, Hofmann I, Yang D, Zhong X, Padron E, Zhou L, Pear WS, Zhang J.

Leukemia. 2019 Mar;33(3):671-685. doi: 10.1038/s41375-018-0248-0. Epub 2018 Sep 11.

26.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.

27.

Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML.

Niyongere S, Lucas N, Zhou JM, Sansil S, Pomicter AD, Balasis ME, Robinson J, Kroeger J, Zhang Q, Zhao YL, Ball M, Komrokji R, List A, Deininger MW, Fridley BL, Santini V, Solary E, Padron E.

Leukemia. 2019 Jan;33(1):205-216. doi: 10.1038/s41375-018-0203-0. Epub 2018 Jul 19.

PMID:
30026572
28.

Motivations and Experiences of People Seeking Medication Abortion Online in the United States.

Aiken ARA, Broussard K, Johnson DM, Padron E.

Perspect Sex Reprod Health. 2018 Dec;50(4):157-163. doi: 10.1363/psrh.12073. Epub 2018 Jul 11.

PMID:
29992793
29.

Experiences of women in Ireland who accessed abortion by travelling abroad or by using abortion medication at home: a qualitative study.

Aiken ARA, Johnson DM, Broussard K, Padron E.

BMJ Sex Reprod Health. 2018 May 15. pii: bmjsrh-2018-200113. doi: 10.1136/bmjsrh-2018-200113. [Epub ahead of print]

PMID:
29972360
30.

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.

Coombs CC, Gillis NK, Tan X, Berg JS, Ball M, Balasis ME, Montgomery ND, Bolton KL, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, Knepper TC, Soper JT, Weiss J, Grilley-Olson JE, Kim WY, Earp HS 3rd, Levine RL, Papaemmanuil E, Zehir A, Hayes DN, Padron E.

Clin Cancer Res. 2018 Dec 1;24(23):5918-5924. doi: 10.1158/1078-0432.CCR-18-1201. Epub 2018 Jun 4.

31.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Duchmann M, Yalniz FF, Sanna A, Sallman D, Coombs CC, Renneville A, Kosmider O, Braun T, Platzbecker U, Willems L, Adès L, Fontenay M, Rampal R, Padron E, Droin N, Preudhomme C, Santini V, Patnaik MM, Fenaux P, Solary E, Itzykson R.

EBioMedicine. 2018 May;31:174-181. doi: 10.1016/j.ebiom.2018.04.018. Epub 2018 Apr 25.

32.

Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.

Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK.

Blood. 2018 May 24;131(21):2402-2405. doi: 10.1182/blood-2018-01-827881. Epub 2018 Apr 16. No abstract available.

33.

Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

Hussaini MO, Mirza AS, Komrokji R, Lancet J, Padron E, Song J.

Cancer Genomics Proteomics. 2018 Mar-Apr;15(2):121-126.

34.

H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.

Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, Agrawal AA, Caleb B, Csibi A, Sean E, Fekkes P, Karr C, Klimek V, Lai G, Lee L, Kumar P, Lee SC, Liu X, Mackenzie C, Meeske C, Mizui Y, Padron E, Park E, Pazolli E, Peng S, Prajapati S, Taylor J, Teng T, Wang J, Warmuth M, Yao H, Yu L, Zhu P, Abdel-Wahab O, Smith PG, Buonamici S.

Nat Med. 2018 May;24(4):497-504. doi: 10.1038/nm.4493. Epub 2018 Feb 19.

35.

Value of Placental Volume and Vascular Flow Indices as Predictors of Early and Late Preeclampsia at First Trimester.

González-González NL, González Dávila E, Padrón E, Armas Gonzalez M, Plasencia W.

Fetal Diagn Ther. 2018;44(4):256-263. doi: 10.1159/000481433. Epub 2018 Jan 23.

PMID:
29393218
36.

Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Br J Haematol. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23. No abstract available.

PMID:
29359794
37.

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.

PMID:
29189896
38.

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS.

Sallman DA, Komrokji R, Cluzeau T, Vaupel C, Al Ali NH, Lancet J, Hall J, List A, Padron E, Song J.

Blood Cancer J. 2017 Nov 27;7(12):633. doi: 10.1038/s41408-017-0004-0. No abstract available.

39.

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS.

Ann Hematol. 2018 Feb;97(2):247-254. doi: 10.1007/s00277-017-3186-4. Epub 2017 Nov 22.

PMID:
29167940
40.

Chipping in on clonal hematopoiesis.

Gillis NK, Padron E.

Oncotarget. 2017 Oct 4;8(49):84637-84638. doi: 10.18632/oncotarget.21472. eCollection 2017 Oct 17. No abstract available.

41.

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.

PMID:
29030092
42.

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.

J Natl Compr Canc Netw. 2017 Oct;15(10):1193-1207. doi: 10.6004/jnccn.2017.0157.

PMID:
28982745
43.

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.

PMID:
28869184
44.

Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E.

Leukemia. 2018 Feb;32(2):532-538. doi: 10.1038/leu.2017.184. Epub 2017 Jun 21.

PMID:
28694526
45.

TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Kharfan-Dabaja MA, Komrokji RS, Zhang Q, Kumar A, Tsalatsanis A, Perkins J, Nishihori T, Field T, Al Ali N, Mishra A, Sallman D, Salem KZ, Zhang L, Moscinski L, Fernandez HF, Lancet J, List A, Anasetti C, Padron E.

Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):753-758. doi: 10.1016/j.clml.2017.06.003. Epub 2017 Jun 16.

46.

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Erratum in: Blood. 2017 Sep 28;130(13):1602.

47.

Myelodysplasia in younger adults: outlier or unique molecular entity?

Sallman DA, Padron E.

Haematologica. 2017 Jun;102(6):967-968. doi: 10.3324/haematol.2017.165993. No abstract available.

48.

Value of placental volume and vascular flow indices as predictors of intrauterine growth retardation.

González-González NL, González-Dávila E, González Marrero L, Padrón E, Conde JR, Plasencia W.

Eur J Obstet Gynecol Reprod Biol. 2017 May;212:13-19. doi: 10.1016/j.ejogrb.2017.03.005. Epub 2017 Mar 6.

PMID:
28327375
49.

Trauma Type and Posttraumatic Stress Disorder as Predictors of Parenting Stress in Trauma-Exposed Mothers.

Wilson CK, Padrón E, Samuelson KW.

Violence Vict. 2017 Feb 1;32(1):141-158. doi: 10.1891/0886-6708.VV-D-13-00077.

PMID:
28234203
50.

Detection of Novel t(12;17)(p12;p13) in Relapsed Refractory Acute Myeloid Leukemia by Anchored Multiplex PCR(AMP)-based Next-Generation Sequencing.

Badar T, Johnson L, Trifilo K, Wang H, Kudlow BA, Padron E, Pappenhausen PR, Hussaini MO.

Appl Immunohistochem Mol Morphol. 2019 Mar;27(3):e28-e31. doi: 10.1097/PAI.0000000000000477.

PMID:
28187034

Supplemental Content

Loading ...
Support Center